Waterfront Wealth Inc. cut its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) by 46.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,843 shares of the medical equipment provider’s stock after selling 8,675 shares during the period. Waterfront Wealth Inc.’s holdings in Lantheus were worth $747,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors also recently modified their holdings of the stock. M&T Bank Corp acquired a new position in Lantheus during the 4th quarter worth $370,950,000. Farallon Capital Management LLC increased its stake in shares of Lantheus by 56.1% in the 4th quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock valued at $361,199,000 after buying an additional 1,950,252 shares during the period. Reinhart Partners LLC. raised its position in shares of Lantheus by 15.9% during the fourth quarter. Reinhart Partners LLC. now owns 1,562,576 shares of the medical equipment provider’s stock worth $103,990,000 after acquiring an additional 214,820 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Lantheus by 3.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,415,463 shares of the medical equipment provider’s stock worth $94,202,000 after acquiring an additional 44,374 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Lantheus during the fourth quarter worth $76,197,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several research firms recently issued reports on LNTH. B. Riley Financial raised their price target on Lantheus from $97.00 to $129.00 and gave the company a “buy” rating in a report on Thursday. The Goldman Sachs Group restated a “neutral” rating and set a $94.00 target price on shares of Lantheus in a research report on Thursday, May 7th. Citigroup reiterated an “outperform” rating on shares of Lantheus in a research report on Friday, May 8th. Weiss Ratings restated a “hold (c)” rating on shares of Lantheus in a report on Tuesday, May 26th. Finally, Wall Street Zen cut shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $108.29.
Lantheus Trading Down 0.3%
Shares of NASDAQ:LNTH traded down $0.35 during mid-day trading on Friday, reaching $105.64. The stock had a trading volume of 942,439 shares, compared to its average volume of 903,660. The firm has a market cap of $6.88 billion, a PE ratio of 25.46 and a beta of -0.06. The firm has a 50 day simple moving average of $100.71 and a two-hundred day simple moving average of $82.90. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $111.86.
Lantheus (NASDAQ:LNTH – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The firm had revenue of $377.33 million during the quarter, compared to analysts’ expectations of $354.48 million. During the same quarter in the previous year, the company earned $1.53 earnings per share. The business’s revenue for the quarter was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, research analysts predict that Lantheus Holdings, Inc. will post 4.49 EPS for the current fiscal year.
Lantheus Profile
Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.
The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.
Featured Articles
- Five stocks we like better than Lantheus
- Starbucks Builds Sovereign AI to Cut $400 Million in Software Costs
- Power Struggle: Wolfspeed Sues Navitas Over AI Chips
- Why WD-40 Is Proving Great Businesses Never Go Out of Style
- Pushing the Edge: Super Micro Computer Reboots the AI Landscape
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.
